FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200538081> ?p ?o ?g. }

• W4200538081 endingPage "144" @default.
• W4200538081 startingPage "133" @default.
• W4200538081 abstract "Novel therapeutic strategies are needed in the fight against pancreatic cancer. We have previously documented the chemopreventive effect of MDC-22 in preclinical models of pancreatic cancer. In the present work, we examined the therapeutic effects of MDC-22 in patient-derived tumor xenografts (PDTXs) and in LSL-KrasG12D/+, LSL-Trp53R172H/+, Pdx1-Cre (KPC) genetically engineered mice, two complementary and clinically relevant animal models of pancreatic cancer. In addition, we evaluated whether MDC-22 could synergize with current chemotherapeutic drugs used in the clinic. MDC-22 reduced the growth of various human pancreatic cancer cell lines in a concentration-dependent manner. In vivo, MDC-22 strongly reduced patient-derived pancreatic tumor xenograft growth by 50%, and extended survival of LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre (KPC) mice by over a month (5.3 months versus 7.0 months). In both models, MDC-22 inhibited EGFR activation and its downstream signals, including ERK and FAK phosphorylation. In human pancreatic cancer cell lines, MDC-22 enhanced the growth inhibitory effect of irinotecan, and to a lesser degree those of gemcitabine and nab-paclitaxel. Normal human pancreatic epithelial cells were more resistant to the cytotoxic effects of, both, MDC-22 alone or in combination with irinotecan, indicating selectivity. Furthermore, MDC-22 enhanced irinotecan's effect on cell migration, in part, by inhibiting EGFR/FAK signaling. Collectively, our results indicate that MDC-22 is an effective anticancer drug in preclinical models of pancreatic cancer, and suggest that MDC-22 plus irinotecan as drug combination strategy for pancreatic cancer treatment, which warrants further evaluation." @default.
• W4200538081 created "2021-12-31" @default.
• W4200538081 creator A5006197121 @default.
• W4200538081 creator A5026796732 @default.
• W4200538081 creator A5077319702 @default.
• W4200538081 creator A5079097444 @default.
• W4200538081 date "2022-02-01" @default.
• W4200538081 modified "2023-10-01" @default.
• W4200538081 title "Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan" @default.
• W4200538081 cites W1522220253 @default.
• W4200538081 cites W1923273052 @default.
• W4200538081 cites W1969201526 @default.
• W4200538081 cites W1974964199 @default.
• W4200538081 cites W1989204587 @default.
• W4200538081 cites W1992995822 @default.
• W4200538081 cites W2034441854 @default.
• W4200538081 cites W2040198910 @default.
• W4200538081 cites W2044423100 @default.
• W4200538081 cites W2056837505 @default.
• W4200538081 cites W2061879830 @default.
• W4200538081 cites W2085768428 @default.
• W4200538081 cites W2088573644 @default.
• W4200538081 cites W2099383868 @default.
• W4200538081 cites W2115658806 @default.
• W4200538081 cites W2129140055 @default.
• W4200538081 cites W2130186290 @default.
• W4200538081 cites W2137407924 @default.
• W4200538081 cites W2144398239 @default.
• W4200538081 cites W2154554776 @default.
• W4200538081 cites W2165480504 @default.
• W4200538081 cites W2262915357 @default.
• W4200538081 cites W2346956937 @default.
• W4200538081 cites W2469223980 @default.
• W4200538081 cites W2574695762 @default.
• W4200538081 cites W2590002384 @default.
• W4200538081 cites W2790768119 @default.
• W4200538081 cites W2800476525 @default.
• W4200538081 cites W2900728807 @default.
• W4200538081 cites W2903623792 @default.
• W4200538081 cites W2944210961 @default.
• W4200538081 cites W2966911669 @default.
• W4200538081 cites W2968952801 @default.
• W4200538081 cites W2977581043 @default.
• W4200538081 cites W2999417355 @default.
• W4200538081 cites W3002714400 @default.
• W4200538081 cites W3009108530 @default.
• W4200538081 cites W4210976084 @default.
• W4200538081 cites W4211181525 @default.
• W4200538081 cites W72550747 @default.
• W4200538081 cites W935022509 @default.
• W4200538081 doi "https://doi.org/10.1016/j.neo.2021.12.004" @default.
• W4200538081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34968866" @default.
• W4200538081 hasPublicationYear "2022" @default.
• W4200538081 type Work @default.
• W4200538081 citedByCount "3" @default.
• W4200538081 countsByYear W42005380812022 @default.
• W4200538081 countsByYear W42005380812023 @default.
• W4200538081 crossrefType "journal-article" @default.
• W4200538081 hasAuthorship W4200538081A5006197121 @default.
• W4200538081 hasAuthorship W4200538081A5026796732 @default.
• W4200538081 hasAuthorship W4200538081A5077319702 @default.
• W4200538081 hasAuthorship W4200538081A5079097444 @default.
• W4200538081 hasBestOaLocation W42005380811 @default.
• W4200538081 hasConcept C121608353 @default.
• W4200538081 hasConcept C126322002 @default.
• W4200538081 hasConcept C144369459 @default.
• W4200538081 hasConcept C150903083 @default.
• W4200538081 hasConcept C207001950 @default.
• W4200538081 hasConcept C2777292972 @default.
• W4200538081 hasConcept C2777996000 @default.
• W4200538081 hasConcept C2780210213 @default.
• W4200538081 hasConcept C2780258809 @default.
• W4200538081 hasConcept C2780259306 @default.
• W4200538081 hasConcept C502942594 @default.
• W4200538081 hasConcept C526805850 @default.
• W4200538081 hasConcept C71924100 @default.
• W4200538081 hasConcept C86803240 @default.
• W4200538081 hasConcept C98274493 @default.
• W4200538081 hasConceptScore W4200538081C121608353 @default.
• W4200538081 hasConceptScore W4200538081C126322002 @default.
• W4200538081 hasConceptScore W4200538081C144369459 @default.
• W4200538081 hasConceptScore W4200538081C150903083 @default.
• W4200538081 hasConceptScore W4200538081C207001950 @default.
• W4200538081 hasConceptScore W4200538081C2777292972 @default.
• W4200538081 hasConceptScore W4200538081C2777996000 @default.
• W4200538081 hasConceptScore W4200538081C2780210213 @default.
• W4200538081 hasConceptScore W4200538081C2780258809 @default.
• W4200538081 hasConceptScore W4200538081C2780259306 @default.
• W4200538081 hasConceptScore W4200538081C502942594 @default.
• W4200538081 hasConceptScore W4200538081C526805850 @default.
• W4200538081 hasConceptScore W4200538081C71924100 @default.
• W4200538081 hasConceptScore W4200538081C86803240 @default.
• W4200538081 hasConceptScore W4200538081C98274493 @default.
• W4200538081 hasFunder F4320332564 @default.
• W4200538081 hasFunder F4320337351 @default.
• W4200538081 hasIssue "2" @default.
• W4200538081 hasLocation W42005380811 @default.
• W4200538081 hasLocation W42005380812 @default.

• next